La expansión de opciones terapéuticas en cáncer de próstata y el uso de radiofarmacos continúa. Estudio fase 3, 177Lu-PSMA I&T, con endpoint primario positivo rPFS. Conoce más 👇👇 Julián G. Rojas Camacho Danny Mena Cortes Cecilia Carreras Velázquez Isabel Hume Diego Martin Barreiro Federico Losco Mauricio Fernández Lazzaro Tomás Soulé Daniel Castellano Juan Antonio Vallejo Casas https://lnkd.in/efQtdg5y
UroTeragLATAM
Health and Human Services
Somos un grupo multidisciplinario de uro-oncología en LATAM enfocados en la enseñanza de teragnóstico.
About us
- Website
-
www.uroteraglatam.com
External link for UroTeragLATAM
- Industry
- Health and Human Services
- Company size
- 2-10 employees
- Type
- Privately Held
Updates
-
We believe collaboration is the way to raise awareness about men's health. Today UroTeragLATAM was present supporting First “Carrera Celeste” in Argentina. Congrats to all organizers !! Federico Losco Danny Mena Cortes Novedades en Urooncología Curso de actualización en Urooncología Diego Martin Barreiro
-
-
-
-
-
+3
-
-
Estuvimos presentes en UroTarget, evento académico referente de la Uro-Oncología en Mendoza, Argentina. Nuestro espacio “De la evidencia a la práctica clínica en Teragnostico” tuvo gran acogida. Gracias a los organizadores por la invitación Federico Losco Mauricio Fernández Lazzaro y felicidades a nuestros representantes Daniel Castellano Danny Mena Cortes Isabel Hume por su participación. Nos vemos en UroTarget 2025!!
-
-
-
-
-
+1
-
-
El Teragnóstico en cáncer de próstata continúa su avance. En @smumexico juntaremos un gran equipo multidisciplinario para desplegar la evidencia actual. @RomanCarvajal Danny Mena Cortes Daniel Castellano Diego Martin Barreiro Julián G. Rojas Camacho Cecilia Carreras Velázquez Professor Declan Murphy #SMU24
-
-
La educación teragnóstica regional continúa avanzando!!! En pocos días estaremos en UroTarget Mendoza, Argentina; llevando a cabo una actividad inmersiva con casos en tiempo real junto a Daniel Castellano 🇪🇸 , Isabel Hume 🇦🇷 y Danny Mena Cortes 🇲🇽 Gracias a Mauricio Fernández Lazzaro y Federico Losco por el espacio. Actividad académica con el apoyo de ITM Isotope Technologies Munich SE Scintomics Molecular ATT Nuclear Medicine World Isotopia Molecular Imaging ltd Tecnonuclear MIM Software
-
-
UroTeragLATAM presente en la “Primera Carrera Celeste en Argentina” por la concientización del cáncer de próstata y el cuidado de la salud masculina. Inscríbete y apoya esta gran iniciativa!! 👇👇👇 https://lnkd.in/eM928_DM
-
-
RECIP Criteria in 223Ra therapy evaluation 👇👇👇
𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗱𝘂𝗿𝗶𝗻𝗴 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟯 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗨𝘀𝗶𝗻𝗴 𝗣𝗦𝗠𝗔-𝗣𝗘𝗧/𝗖𝗧 𝙆𝙚𝙮 𝙄𝙣𝙨𝙞𝙜𝙝𝙩: PSMA-PET/CT performed after 3 cycles of Radium-223 therapy is prognostic for overall survival. Pairs of baseline and post-therapy PSMA-PET/CT scans, interpreted according to RECIP 1.0 and PPP criteria, were associated with overall survival (C-index: 0.66 vs. 0.63). 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙄𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙖𝙩𝙞𝙤𝙣: PSMA-PET/CT imaging can effectively evaluate treatment response in patients with metastatic castration-resistant prostate cancer undergoing Radium-223. Interpretation of PSMA-PET/CT images using RECIP 1.0 demonstrated better performance compared to PPP criteria. 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧 𝙢𝙤𝙧𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/ewAD-uY6 Qaid Shagera, MD, PhD | Carlos Artigas #PSMA #RECIP
-
-
Quieres conocer el rol de PET-PSMA en pacientes con sospecha de cáncer de próstata? PRIMARY SCORE!! Aca puedes encontrar los tips de cómo interpretarlo: 👇👇👇 https://lnkd.in/eX3Fas7p Louise Emmett Diego Martin Barreiro Danny Mena Cortes Julián G. Rojas Camacho Fabián YABER Isabel Hume Cecilia Carreras Velázquez
Professor (conjoint) UNSW Director of Theranostics and Nuclear medicine, St Vincent's Hospital Sydney
primaryscore.com is a free online educational website designed to teach how to optimally use the PRIMARY score for when PSMA-PET/CT is used in the diagnosis of prostate cancer. Sign up and take the online quiz, watch the podcast explanations of both the PRIMARY score, prostate MRI reporting and prostate anatomy and an online MDT session of difficult cases. Website developed by A/Prof Narjess Ayati, supported by St Vincent's Hospital Sydney, Australia and St Vincent's Curran Foundation.
Home | primaryscore
primaryscore.com
-
UroTeragLATAM reposted this
‼️‼️‼️ 14 y 15 de Noviembre se llevará a cabo el SUMMIT VIRTUAL: Radiotheranostics: New Era for Alpha Emittersand Radiopharmaceuticals. Programa científico de mas de 10 horas, modalidad virtual a cargo de Prof. Giesel y Prof. Baum, pioneros en Radioteranostico. Descuento especial para la comunidad UroTeragLATAM. No dejen pasar esta oportunidad.
ICPO Foundation-International Centers for Precision Oncology Theranostics Virtual Summit 2024!! Odile JAUME Agolti Mariela Richard P. Baum Danny Mena Cortes Cecilia Carreras Velázquez
-
-
PSMAfore trial: un nuevo horizonte de uso temprano (previo a taxanos) de 177Lu-PSMA en cáncer de próstata resistente a la castración. Conoce más 👇👇👇 Daniel Castellano Danny Mena Cortes Advanced Prostate Cancer Consensus Conference Michael Hofman Louise Emmett The Lancet
PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer out on The Lancet https://lnkd.in/dCH9xJPb In a phase 3 trial, [177Lu]Lu-PSMA-617 significantly improved radiographic progression-free survival compared to a change in androgen receptor pathway inhibitors (ARPI) in taxane-naive patients with PSMA-positive metastatic castration-resistant #ProstateCancer . With a median follow-up of 24.1 months, the 177Lu-PSMA-617 group had a median progression-free survival of 11.6 months versus 5.6 months in the ARPI change group. The safety profile of 177Lu-PSMA-617 was favorable, showing fewer severe adverse events compared to the ARPI change group. These results suggest that 177Lu-PSMA-617 could be an effective treatment alternative for patients who have progressed on prior ARPI therapy. Daniel Castellano Ken Herrmann Johann de Bono Neal Shore Michael Crosby Josep M Piulats Flechon Aude Mahammedi Hakim Guilhem Roubaud Prof. Dr. med. James Nagarajah Begoña Mellado González Euloge Kpamegan Samson Ghebremariam Teri Kreisl Dr. med. Celine Wilke Oliver Sartor @Karim Fizazi
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
thelancet.com